mRNA Beyond Vaccines: Expanding Applications in Pharma
When most of us think of mRNA technology, COVID-19 vaccines instantly come to mind. But mRNA is not just a vaccine superstar, it’s an emerging powerhouse in pharmaceutical innovation.
September 12, 2025
by Nurah Ekhlaque
Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company
Dx&Vx (DXVX) has signed its first-ever global out-licensing agreement since its establishment.
July 31, 2025
by PR Newswire
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
AIM Vaccine's mRNA shingles vaccine got FDA clinical trial approval. Its platform has advantages, AI empowers it, and the vaccine market has great potential.
March 24, 2025
by PR Newswire
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
Another Step Forward in Global Expansion
February 25, 2025
by PR Newswire
Dx&Vx, From mRNA Vaccines to Nanoparticle Vaccines era of Next-Generation Vaccines
The COVID-19 pandemic has fundamentally transformed global healthcare systems and vaccine technologies.
January 8, 2025
by PRNewswire
Africa Expands Vaccine Manufacturing Capacity
The outbreak of COVID-19 pandemic has revived the drive by governments in Africa to expand local pharmaceutical manufacturing so as to increase access to affordable quality medicines for the continent’s 1.3 billion people.
March 8, 2022
by Shem Oirere
Third mRNA Vaccine Dose Ups Effectiveness Against Hospitalization
Receipt of a third COVID-19 mRNA vaccine dose is associated with increased vaccine effectiveness against COVID-19 hospitalization...
January 27, 2022
by drugs.com
Moderna and Carisma collaborate to develop in-vivo engineered CAR-M for oncology
The companies have partnered to discover, develop and commercialise in-vivo engineered Chimeric Antigen Receptor Monocyte (CAR-M) therapeutics for the treatment of cancer.
January 11, 2022
by ExpressPharma
China rushes to develop an mRNA vaccine as doubts grow over local jabs
China's race to develop its own mRNA vaccine against COVID-19 has gained greater urgency as Beijing struggles to rein in an outbreak of the Omicron coronavirus variant that is threatening its "zero-Covid" policy, reported the Financial Times.
January 7, 2022
by FirstWordPharma
Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a revised supply agreement with the government of South Korea for 20 million doses...
December 28, 2021
by FirstWordPharma
Curia Launches Comprehensive mRNA Offering
mRNA services combine experience and capabilities from discovery through fill-finish manufacturing.
December 22, 2021
by contractpharma
Supported by Capital, the Application of mRNA Technology has Become a Hot Field in China
In the middle of August, Abogen Biosciences announced that it had completed a third round of financing with its total amount exceeding 700 million US dollars, which set a new record for single financing before IPO of Chinese biopharmaceutical companies.
December 17, 2021
by PharmaSources/Xiaoyaowan